Brian E. Cathers

5.6k total citations · 3 hit papers
31 papers, 2.6k citations indexed

About

Brian E. Cathers is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Brian E. Cathers has authored 31 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 17 papers in Hematology and 7 papers in Oncology. Recurrent topics in Brian E. Cathers's work include Protein Degradation and Inhibitors (15 papers), Multiple Myeloma Research and Treatments (12 papers) and Ubiquitin and proteasome pathways (10 papers). Brian E. Cathers is often cited by papers focused on Protein Degradation and Inhibitors (15 papers), Multiple Myeloma Research and Treatments (12 papers) and Ubiquitin and proteasome pathways (10 papers). Brian E. Cathers collaborates with scholars based in United States, Switzerland and Japan. Brian E. Cathers's co-authors include Sean M. Kerwin, Daekyu Sun, Laurence H. Hurley, Terence C. Jenkins, Stephen Neidle, Miguel Salazar, Brian Thompson, John O. Trent, Philip P. Chamberlain and Antonia Lopez‐Girona and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Blood.

In The Last Decade

Brian E. Cathers

31 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of Human Telomerase by a G-Quadruplex-Interactive Compound

1997 664 citations Daekyu Sun, Brian Thompson et al. Journal of Medicinal Chemistry profile →
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide

2012 606 citations Antonia Lopez‐Girona, Derek Mendy et al. Leukemia profile →
Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs

2014 371 citations Philip P. Chamberlain, Antonia Lopez‐Girona et al. Nature Structural & Molecular Biology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brian E. Cathers United States	17	2.2k	904	619	148	143	31	2.6k
Katherine A. Donovan United States	30	3.3k 1.5×	835 0.9×	1.4k 2.2×	70 0.5×	125 0.9×	86	3.7k
Kevin D. Shenk United States	10	1.5k 0.7×	860 1.0×	698 1.1×	29 0.2×	135 0.9×	18	1.9k
Jessica Adickes United States	4	1.4k 0.6×	200 0.2×	548 0.9×	114 0.8×	204 1.4×	4	1.9k
Yuan Xiao Zhu United States	19	1.4k 0.6×	945 1.0×	494 0.8×	32 0.2×	108 0.8×	47	1.8k
Rekha Rao United States	25	1.8k 0.8×	506 0.6×	401 0.6×	41 0.3×	281 2.0×	49	2.2k
Ronald M. Paranal United States	11	1.8k 0.8×	264 0.3×	480 0.8×	35 0.2×	64 0.4×	17	2.2k
Michael A. Koldobskiy United States	14	1.7k 0.8×	239 0.3×	516 0.8×	143 1.0×	126 0.9×	26	2.3k
Courtney G. Havens United States	13	1.3k 0.6×	376 0.4×	508 0.8×	30 0.2×	66 0.5×	16	1.6k
Yukimasa Shiotsu Japan	22	1.1k 0.5×	427 0.5×	305 0.5×	33 0.2×	175 1.2×	47	1.8k
Kevin G. McLure United States	16	1.6k 0.7×	268 0.3×	794 1.3×	54 0.4×	32 0.2×	24	1.9k

Countries citing papers authored by Brian E. Cathers

Since Specialization

Citations

This map shows the geographic impact of Brian E. Cathers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian E. Cathers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian E. Cathers more than expected).

Fields of papers citing papers by Brian E. Cathers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian E. Cathers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian E. Cathers. The network helps show where Brian E. Cathers may publish in the future.

Co-authorship network of co-authors of Brian E. Cathers

This figure shows the co-authorship network connecting the top 25 collaborators of Brian E. Cathers. A scholar is included among the top collaborators of Brian E. Cathers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian E. Cathers. Brian E. Cathers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dufu, Kobina, Carsten Alt, Steven Strutt, et al.. (2023). GBT021601 improves red blood cell health and the pathophysiology of sickle cell disease in a murine model. British Journal of Haematology. 202(1). 173–183. 6 indexed citations

Potdar, Alka A., Carsten Alt, Francis DeGuzman, et al.. (2023). Predictive Biomarker Analysis from the GBT021601 Survival Study in Townes Sickle Mice. Blood. 142(Supplement 1). 14–14. 2 indexed citations

Dufu, Kobina, Carsten Alt, Steven Strutt, et al.. (2020). GBT021601 Inhibits HbS Polymerization, Prevents RBC Sickling and Improves the Pathophysiology of Sickle Cell Disease in a Murine Model. Blood. 136(Supplement 1). 7–8. 4 indexed citations

Chamberlain, Philip P. & Brian E. Cathers. (2019). Cereblon modulators: Low molecular weight inducers of protein degradation. Drug Discovery Today Technologies. 31. 29–34. 79 indexed citations

Lopez‐Girona, Antonia, Gang Lu, Emily Rychak, et al.. (2019). CC-90009, a Novel Cereblon E3 Ligase Modulator, Targets GSPT1 for Degradation to Induce Potent Tumoricidal Activity Against Acute Myeloid Leukemia (AML). Blood. 134(Supplement_1). 2703–2703. 16 indexed citations

Nguyen, Thang Van, Jing Li, Chin-Chun Lu, et al.. (2017). p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates. Proceedings of the National Academy of Sciences. 114(14). 3565–3571. 68 indexed citations

Rychak, Emily, Derek Mendy, Tao Shi, et al.. (2016). Pomalidomide in combination with dexamethasone results in synergistic anti‐tumour responses in pre‐clinical models of lenalidomide‐resistant multiple myeloma. British Journal of Haematology. 172(6). 889–901. 40 indexed citations

Chamberlain, Philip P., S.L. Delker, Barbra Pagarigan, et al.. (2014). Crystal Structures of PRK1 in Complex with the Clinical Compounds Lestaurtinib and Tofacitinib Reveal Ligand Induced Conformational Changes. PLoS ONE. 9(8). e103638–e103638. 11 indexed citations

Chamberlain, Philip P., Antonia Lopez‐Girona, Karen Miller, et al.. (2014). Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nature Structural & Molecular Biology. 21(9). 803–809. 371 indexed citations breakdown →

10.

Fecteau, Jessie-F., Laura G. Corral, Emanuela M. Ghia, et al.. (2014). Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21WAF1/Cip1-dependent mechanism independent of functional p53. Blood. 124(10). 1637–1644. 64 indexed citations

11.

Gandhi, Anita K., Derek Mendy, Michelle F. Waldman, et al.. (2013). Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. British Journal of Haematology. 164(2). 233–244. 71 indexed citations

12.

Lopez‐Girona, Antonia, Derek Mendy, Takumi Ito, et al.. (2012). Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 26(11). 2326–2335. 606 indexed citations breakdown →

13.

Xu, Shuichan, Mahan Abbasian, Kristen Jensen-Pergakes, et al.. (2007). Substrate Recognition and Ubiquitination of SCFSkp2/Cks1 Ubiquitin-Protein Isopeptide Ligase. Journal of Biological Chemistry. 282(21). 15462–15470. 20 indexed citations

14.

Sergeeva, Oksana A., et al.. (2003). Kinetic properties of human thymidylate synthase, an anticancer drug target. Biochemical and Biophysical Research Communications. 307(2). 297–300. 11 indexed citations

15.

Sergeeva, Maria V. & Brian E. Cathers. (2003). Cellular transformation of the investigational new anticancer drug NB1011, a phosphoramidate of 5-(2-bromovinyl)-2′-deoxyuridine, results in modification of cellular proteins not DNA. Biochemical Pharmacology. 65(5). 823–831. 7 indexed citations

16.

Cathers, Brian E., et al.. (2002). pH Dependence of inhibitors targeting the occluding loop of cathepsin B. Bioorganic Chemistry. 30(4). 264–275. 18 indexed citations

17.

Fletcher, Terace M., et al.. (2001). Inhibition of Human Telomerase by 7-Deaza-2′-deoxyguanosine Nucleoside Triphosphate Analogs: Potent Inhibition by 6-Thio-7-deaza-2′-deoxyguanosine 5′-Triphosphate. Bioorganic Chemistry. 29(1). 36–55. 47 indexed citations

18.

Cathers, Brian E. & John V. Schloss. (1999). The sulfonimidamide as a novel transition state analog for aspartic acid and metallo proteases. Bioorganic & Medicinal Chemistry Letters. 9(11). 1527–1532. 30 indexed citations

19.

Sun, Daekyu, Brian Thompson, Brian E. Cathers, et al.. (1997). Inhibition of Human Telomerase by a G-Quadruplex-Interactive Compound. Journal of Medicinal Chemistry. 40(14). 2113–2116. 664 indexed citations breakdown →

20.

Cathers, Brian E. & John V. Schloss. (1996). Enzyme-Coupled Assays for Proteases. Analytical Biochemistry. 241(1). 1–4. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact